GlassScriptPhysician profile
Daniel L Borgstadt
NPI 1457332330
$6,799.22
in general payments reported to CMS, 2019-2025
52 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,040 · 2020: $1,342 · 2021: $659 · 2022: $422 · 2023: $841 · 2024: $803 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $977.83 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $807.85 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $542.54 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $360.61 | 2019-2024 | |
| Lilly USA, LLC | $337.82 | 2019-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $313.35 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $301.64 | 2019-2023 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.79 | 2019-2021 | |
| Esperion Therapeutics, INC. | $219.69 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $206.00 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $188.01 | 2019-2021 | |
| Teleflex LLC | $171.97 | 2025 | Urolift |
| Abbott Laboratories | $163.73 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $153.82 | 2019-2020 | |
| Astellas Pharma US INC | $142.62 | 2019 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Borgstadt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.